Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies

Cancer

Volumn 83, Issue 6, 1998, Pages 1224-1230

  Zuckerman, Eli ^a,b   Zuckerman, Tsila ^a   Douer, Dan ^a   Qian, Dajun ^a   Levine, Alexandra M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Chemotherapy; Fulminant hepatitis; Hematologic malignancies; Hepatitis C virus; Liver dysfunction

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; HYDROXYUREA; MELPHALAN; PREDNISONE; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; HEMATOPOIETIC SYSTEM TUMOR; HEPATITIS C; HEPATITIS C VIRUS; HODGKIN DISEASE; HUMAN; LIVER FUNCTION TEST; MALE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; VIRUS HEPATITIS;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FEMALE; HEPATITIS C; HODGKIN DISEASE; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; LIVER; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA;

EID: 0032530425     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6     Document Type: Article

References (37)

1. Kuo G, Choo Q-L, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
2. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genom. Science 1989;244: 359-62.
3. Dienes HP, Popper H, Arnold W, Lobeck H. Histologic observations in human hepatitis non-A, non-B. Hepatology 1982;2:562-71.
4. Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994;107:196-9.
5. Bertoletti A, Ferrari C, Fiaccadori F, Penna A, Margolskee R, Schlicht HJ, et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A 1991;88: 10445-9.
6. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Virol 1992;149:3339-44.
7. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96: 447-9.
8. Bird GLA, Smith H, Portmann B, Alexander GJM, Williams R. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive theray in hepatitis B carriers. QJM 1989;73: 895-902.
9. Lok ASF, Liang RHS, Chiu EKW, Wong K-L, Chang T-K, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991;100:182-8.
10. Kanamori H, Fukawa H, Maruta A, Harano H, Kodama F, Matsuzaki M, et al. Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci 1992;303:109-11.
11. Kolho E, Ruutu P, Ruutu T. Hepatitis C infection in BMT patients. Bone Marrow Transplant 1993;11:119-23.
12. Maruta A, Kanamori H, Fukawa H, Harano H, Matsuzaki M, Miyashita H, et al. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplant 1994;13:417-22.
13. Ljungman P, Johansson N, Aschan J, Glaumann H, Lonnqvist B, Ringden O, et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 1995;86:1614-8.
14. Davis GL, Lau JY-N, Urdea MS, Neuwald PD, Wilber JC, Lindsay K, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical amplification in interferon-treated patients. Hepatology 1994;19:1337-41.
15. Nolte FS, Thurnmond C, Fried MW. Preclinical evaluation of AMPLICOR hepatitis C virus test for detection of hepatitis C virus RNA. J Clin Microbiol 1995;33:1775-8.
16. Ohno T, Mitzokami M, Wu R-R, Saleh MG, Ohba K-I, Orito E, et al. A new hepatitis C genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997;35:201-7.
17. Banbini G, Zuffa E, Rosti G, Battista R, D'Emilio E, Leoni F, et al. Long-term outcome of adults with acute myelogenous leukemia: results of a prospective , randomized study of chemotherapy with a minimal follow-up of 7 years. Br J Hematol 1991;77:486-90.
18. Rosenberg SA. ABVD versus MOPP: which is better? J Clin Oicol 1987;5:7.
19. Bolin R, Robinson W, Sutherland J, Hamman R. Busulfan versus hydroxyurea I long term therapy of chronic myelogenous leukemia. Cancer 1982;50:1683-6.
20. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-42.
21. Preisler H, Davis RB, Kirshner J, Dupre E, Richards F 3rd, Hoagland HC, et al., and the Cancer and Leukemia Group B. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 1987;69:1441-9.
22. Nachbaur K, Dietze O, Herold M, Thaler J, Braunsteiner H, Vogel W. Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukemia [letter]. Eur J Hematol 1992; 49:221-3.
23. Tebbi CK, Krischer J, Fernbach DJ, Mahoney DH, Alvarado C, Camitta B. Toxicity of high-dose cytosine arabinoside in the treatment of advanced childhood tumors resistant to conventional therapy: a Pediatric Oncology Group Study. Cancer 1990;66:2064-7.
24. Mondelli MG, Mieli-Vergani G, Alberti A, Vergani B, Portmann B, Eddelston AWLF, et al. Speceficity of the T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are direct against HBV core antigen expressed on the hepatocytes. J Immunol 1982;129:2773-81.
25. Botarelli P, Brunetto M, Minutello M, Calvo P, Unutmaz D, Weiner A, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993;104:580-7.
26. Cerny CA, McHutchinson JC, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, et al. Cytotoxic T lymphocytes response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995;95:521-30.
27. Scullar GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Effect of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981;81:987-91.
28. Rakela J, Redeker AG, Weliky B. Effect of short-term prednisone therapy on aminotransferases levels and hepatitis B virus markers in chronic type B hepatitis. Gastroenterology 1983;84:956-60.
29. Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi E, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994;83:1998-2004.
30. Vento S, Cainelli F, Mirandola F, Cosco L, Di Perri G, Solbiati M, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996;347:92-3.
31. Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti M, Longombardo G, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Hematol 1994;88:392-4.
32. Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996;87:4296-4301.
33. Zignego AL, Ferri C, Giannini C, Caracciolo F, Monti M, La Civita L, et al. Analysis of HCV infection in patients with B-cell non-Hodgkin's lymphoma [abstract]. Hepatology 1995;22:514A.
34. Pioltelli P, Zehender G, Minti G, Monteverde A, Galli M. HCV and non-Hodgkin's lymphoma [letter]. Lancet 1996;347:624-5.
35. Zuckerman E, Rosenvald-Zuckerman T, Levine AM, Duer D, Gutekunst K, Mizokami M, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma. Ann Intern Med 1997;127:423-8.
36. Alter MJ, Margolis HR, Krawczynski K, Judson FM, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
37. Lau JY-N, Davis GL, Prescott LE, Maertens G, Lindsay K, Qian K, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med 1996;124:868-76.